IMAC Holdings, Inc. (BACK): debt financing — IMAC Holdings announces VUMC collaboration for breast cancer biomarker RPPA profiling; issues $84K discounted note

IMAC Holdings, Inc.

One-year research collaboration with Vanderbilt University Medical Center; VUMC supplies 80 FFPE breast-cancer samples, Ignite performs RPPA analysis.
Ignite receives exclusive option to negotiate a worldwide license to jointly developed IP; each party bears own costs.
Issued $84,000 promissory note for $60,000 purchase price; unsecured, matures December 24, 2025.
Initial data packages expected within 2 months of sample receipt; collaboration aims to identify immunotherapy response biomarkers.

item 1.01 item 2.03 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

IMAC Holdings, Inc. incurred loan of $84,000 with a certain lender maturing December 24, 2025.

Instrument: loan
Principal: $84,000
Counterparty: a certain lender
Maturity: December 24, 2025
Event: incurrence

Exact text from the filing

On August 5, 2025, IMAC Holdings, Inc. (the “Company”) issued a promissory note (the “Note”) to a certain lender (the “Lender”) in the aggregate principal amount of $84,000 for an aggregate purchase price from the Lenders of $60,000.

View on SEC.gov

101 debt financings filed in the last 30 days. Browse all debt financings →

IMAC Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001641172-25-022584

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.